Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Therapy switches in fingolimod-treated patients with multiple sclerosis: long-term experience from the German MS Registry

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
646kB
[thumbnail of Supplementary Information]
Preview
PDF (Supplementary Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB

Item Type:Article
Title:Therapy switches in fingolimod-treated patients with multiple sclerosis: long-term experience from the German MS Registry
Creators Name:Frahm, N., Fneish, F., Ellenberger, D., Flachenecker, P., Paul, F., Warnke, C., Kleinschnitz, C., Parciak, T., Krefting, D., Hellwig, K., Haas, J., Rommer, P.S., Stahmann, A. and Zettl, U.K.
Abstract:INTRODUCTIONS: Therapy switches in patients with multiple sclerosis (MS) receiving treatment with fingolimod occur frequently in clinical practice but are not well represented in real-world data. The aim of this study was to identify and characterize treatment switches and reveal sociodemographic/clinical changes over time in fingolimod-treated people with MS (PwMS). METHODS: Data on 2536 fingolimod-treated PwMS extracted from the German MS Registry during different time periods were analyzed (2010-2019). RESULTS: Overall, 28.3% of PwMS were treatment-naïve before fingolimod initiation. Interferon beta (30.7%) was the most common pre-fingolimod treatment. Ocrelizumab (19.8%) was the most frequent subsequent treatment in the 944 patients on fingolimod who switched. Between 2010 and 2019, median disease duration at fingolimod initiation decreased from 8.5 to 7.1 years (p < 0.001), and patients taking fingolimod for ≥ 1 year after treatment initiation decreased from 89.6 to 80.5% (p < 0.001). Females (p < 0.001) and young patients (p = 0.003) showed a shorter time on fingolimod. The most frequent reason for switching was disease activity (relapse/MRI) despite treatment. The annualized relapse rate increased from 0.37 in patients on fingolimod to 0.47 after treatment cessation, decreasing to 0.19 after treatment with a subsequent disease-modifying drug (DMD) was initiated. CONCLUSION: Treatment switches from fingolimod to subsequent DMDs currently occur after shorter treatment durations than 10 years ago, possibly due to the growing treatment spectrum. Planning adequate washout periods is essential and should be done on an individualized basis.
Keywords:Multiple Sclerosis, Fingolimod, Treatment Switches, Rebound, Disease-Modifying Drug
Source:Neurology and Therapy
ISSN:2193-8253
Publisher:Springer
Volume:11
Number:1
Page Range:319–336
Date:March 2022
Official Publication:https://doi.org/10.1007/s40120-021-00320-w
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library